MTHFR Mutation and Supplements: What You Actually Need

MTHFR (methylenetetrahydrofolate reductase) is one of the most searched genetic variants in the consumer health space, and one of the most misrepresented. It is associated with everything from miscarriage to depression to cardiovascular disease in popular coverage, often without adequate nuance about which variants actually cause impairment and to what degree.

This guide aims to cut through the noise: what MTHFR variants actually do, which people need to change their supplements, and what a rational supplementation strategy looks like for confirmed MTHFR carriers.

What MTHFR actually does

MTHFR is an enzyme responsible for converting 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF) — the active, circulating form of folate that donates methyl groups for dozens of biochemical reactions.

The most important downstream use of 5-MTHF is the methylation cycle: 5-MTHF donates its methyl group to homocysteine, converting it to methionine. Methionine is then converted to SAM-e (S-adenosylmethionine), the body's universal methyl donor.

SAM-e is required for:

• DNA methylation (epigenetic regulation)
• Neurotransmitter synthesis (serotonin, dopamine, norepinephrine)
• Myelin synthesis
• Phosphatidylcholine production (cell membranes, liver function)
• Detoxification pathways (COMT, PNMT, and others)

When MTHFR function is reduced, 5-MTHF production is impaired, homocysteine accumulates (since conversion to methionine is reduced), and methylation capacity throughout the body decreases. The degree to which this matters depends critically on which variant you carry.

The two primary variants

C677T (rs1801133): The most clinically significant MTHFR variant. Each copy of the T allele reduces MTHFR enzyme activity:

• CT (heterozygous): ~35-40% reduction in MTHFR activity
• TT (homozygous): ~60-75% reduction in MTHFR activity

TT homozygotes have clearly elevated homocysteine levels, measurably reduced folate utilization, and the clinical relevance of supplementation is best established in this group. CT heterozygotes have a modest reduction that is often compensated by adequate dietary folate intake.

A1298C (rs1801131): Less well understood. A1298C affects MTHFR activity in a different domain than C677T. Homozygous CC: approximately 30-40% reduction in activity. Importantly, A1298C does not elevate homocysteine in the same way as C677T — homocysteine levels are typically normal in isolated A1298C carriers. Clinical significance is less clear.

Compound heterozygotes (C677T + A1298C): Having one copy of each variant (rather than two of the same) can be functionally significant and is associated with moderately impaired methylation. Many practitioners treat compound heterozygotes similarly to C677T TT homozygotes in terms of supplementation.

Why folic acid is the wrong supplement for MTHFR carriers

Folic acid is the synthetic form of vitamin B9. It is not biologically active and requires conversion by DHFR (dihydrofolate reductase) and MTHFR to become 5-MTHF. In individuals with reduced MTHFR activity, this conversion is partially blocked.

Moreover, unconverted folic acid that has not been converted to active folate can accumulate as unmetabolized folic acid (UMFA) in circulation. Research suggests that UMFA may actually impair natural killer cell function and compete with active folates at receptor sites.

Practical implication: If you carry MTHFR C677T (TT) or are compound heterozygous, folic acid in supplements and fortified foods is less effective for you and may accumulate problematically. This is especially important in pregnancy, where adequate folate is critical for neural tube development.

Replace folic acid with: 5-MTHF (L-methylfolate, also labeled as Metafolin, Quatrefolic, or Magnafolate). This bypasses the MTHFR step entirely and is directly usable.

Doses for MTHFR carriers:

• Maintenance (non-pregnant): 400-800mcg 5-MTHF daily
• Pregnancy or periconception: 800-1000mcg 5-MTHF daily (discuss with OB/GYN)
• Higher doses (1-5mg) are used clinically in some cases with significantly elevated homocysteine — requires medical supervision

Methylcobalamin: the right form of B12

Vitamin B12 is a cofactor in the methylation cycle — specifically, methylcobalamin donates a methyl group to help convert homocysteine to methionine alongside 5-MTHF. In MTHFR-impaired methylation, ensuring adequate B12 in its active form matters.

Methylcobalamin vs. cyanocobalamin:

• Cyanocobalamin: the synthetic form in most inexpensive B12 supplements. Requires conversion to methylcobalamin in the body. In people with impaired methylation (MTHFR carriers), this conversion may be less efficient.
• Methylcobalamin: the active, methylated form. Used directly in the methylation cycle without conversion.

Adenosylcobalamin is another active form of B12 important for mitochondrial function, though less relevant specifically to the methylation cycle.

Dose: 500mcg-1mg methylcobalamin daily is typical for maintenance in MTHFR carriers. Sublingual or liquid forms have better bioavailability than oral tablets for some individuals (particularly older adults with reduced intrinsic factor).

TMG (trimethylglycine): the alternative methylation pathway

The body has a backup route for converting homocysteine to methionine that does not rely on MTHFR: the betaine-homocysteine methyltransferase (BHMT) pathway, which uses TMG (trimethylglycine, also called betaine) as the methyl donor.

TMG supplementation activates this alternative pathway and can significantly reduce homocysteine levels independently of folate status. This is particularly useful for MTHFR TT homozygotes with elevated homocysteine.

Evidence: Multiple trials have shown TMG at 2-6g/day significantly reduces homocysteine levels in people with hyperhomocysteinemia. It is also supportive of liver health via its role in phosphatidylcholine synthesis (PEMT pathway).

Dose: 500mg-2g/day for general methylation support. Up to 6g/day in supervised protocols for significantly elevated homocysteine.

Note: TMG is distinct from DMG (dimethylglycine). TMG has three methyl groups and donates two; DMG receives one and becomes sarcosine. TMG is the appropriate supplement.

Riboflavin (B2): the often-missed cofactor

Riboflavin (vitamin B2) is a cofactor for MTHFR itself. MTHFR is a flavoprotein — it requires FAD (flavin adenine dinucleotide, derived from riboflavin) to function. In C677T TT homozygotes specifically, riboflavin supplementation has been shown to meaningfully restore MTHFR enzyme activity.

Key trial: A Northern Ireland study found that riboflavin at 1.6mg/day (just above the RDA) substantially reduced homocysteine levels in C677T TT individuals specifically — but had no effect in CT or CC individuals. This suggests riboflavin is a particularly targeted support for TT homozygotes.

Dose: 1.6-5mg/day for MTHFR TT carriers (riboflavin is water-soluble and very safe). Available as riboflavin 5'-phosphate (the active coenzyme form) or regular riboflavin.

Testing homocysteine: the functional marker

Genetic MTHFR testing tells you what variants you carry, but homocysteine testing tells you whether your methylation is actually impaired.

Homocysteine reference range: Labs report normal as up to 15 µmol/L, but functional medicine practitioners often aim for below 10 µmol/L for optimal methylation and cardiovascular risk reduction.

Elevated homocysteine (above 10-15 µmol/L) in an MTHFR carrier confirms that the variant is functionally significant and that methylation support is warranted. Normal homocysteine in an MTHFR carrier (common in C677T CT and A1298C carriers) suggests the body is compensating adequately with dietary folate.

Test: A standard serum homocysteine test. Ideally done fasted. Recheck after 8-12 weeks of methylfolate + TMG supplementation to confirm reduction.

The over-methylation problem

Not all MTHFR carriers respond perfectly to methylated supplements. Some people — particularly those with certain serotonin sensitivity patterns or anxiety predispositions — experience "over-methylation" symptoms when starting methylfolate:

• Irritability, anxiety, or anger
• Insomnia
• Palpitations
• Headaches

These symptoms reflect excessive methyl group donation to monoamine neurotransmitter pathways, increasing serotonin and dopamine activity too rapidly.

Management:

• Start with a very low dose of methylfolate (100-200mcg) and increase slowly over weeks
• Folinic acid (not methylfolate, but an active intermediate form of folate) can be substituted and may be better tolerated for those who react to methylfolate
• Niacin (vitamin B3) can consume excess methyl groups and reduce over-methylation symptoms — some practitioners use 50-100mg niacin if methylfolate causes anxiety

A practical MTHFR supplement protocol

For confirmed C677T TT or compound heterozygous individuals with elevated homocysteine:

1. Replace folic acid with 5-MTHF: 400-800mcg/day (start low if anxiety-prone)
2. Methylcobalamin: 500mcg-1mg/day
3. TMG: 500mg-1g/day to support alternative homocysteine clearance
4. Riboflavin 5'-phosphate: 2-5mg/day (particularly for TT)
5. Magnesium glycinate: 300-400mg/day (required for COMT and multiple methylation enzymes)
6. Recheck homocysteine at 8-12 weeks

The bottom line

MTHFR variants impair conversion of folic acid to active methylfolate, reducing methylation capacity and elevating homocysteine. The C677T TT genotype has the most established clinical significance. Replace folic acid with 5-MTHF, use methylcobalamin over cyanocobalamin, add TMG for alternative homocysteine clearance, and include riboflavin especially for TT carriers. Measure homocysteine — not just genetics — to confirm functional impairment and track treatment response. Start methylfolate at low doses to avoid over-methylation side effects.

---

Track your homocysteine results and methylation supplement stack over time. Use Optimize free.

Related Articles

• Methylfolate vs Folic Acid: Why the Form of Folate You Take Matters